2020
DOI: 10.3389/fcvm.2020.00117
|View full text |Cite
|
Sign up to set email alerts
|

Compound Heterozygous SCN5A Mutations in Severe Sodium Channelopathy With Brugada Syndrome: A Case Report

Abstract: Aims: Brugada syndrome (BrS) is an inherited cardiac arrhythmia with an increased risk for sudden cardiac death (SCD). About 20% of BrS cases are explained by mutations in the SCN5A gene, encoding the main cardiac sodium Na v 1.5 channel. Here we present a severe case of cardiac sodium channelopathy with BrS caused by SCN5A compound heterozygous mutations. We performed a genetic analysis of SCN5A in a male proband who collapsed during cycling at the age of 2 years. Because of atrial standstill, he received a p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 28 publications
0
3
0
Order By: Relevance
“…Compound heterozygosity is infrequent in SCN5A channelopathies, reported only in 13/2111 (0.62%) of BrS patients [ 31 ], and in 0.7% of neonates with SCN5A mutations [ 15 ]. Moreover, among ten individual SCN5A compound heterozygous case reports [ 12 , 13 , 27 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ], only two cases reported adult age of onset [ 35 , 36 ], and 6/8 childhood onset cases had a truncating mutation combined with a missense mutation [ 12 , 27 , 32 , 33 , 34 ]. All three of our compound heterozygous cases (cases 8, 10 and 13) carried an inferred null and a missense mutation, had a severe overlap syndrome with early childhood onset (<4 years), and NFCA events occurred in two of these cases.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Compound heterozygosity is infrequent in SCN5A channelopathies, reported only in 13/2111 (0.62%) of BrS patients [ 31 ], and in 0.7% of neonates with SCN5A mutations [ 15 ]. Moreover, among ten individual SCN5A compound heterozygous case reports [ 12 , 13 , 27 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ], only two cases reported adult age of onset [ 35 , 36 ], and 6/8 childhood onset cases had a truncating mutation combined with a missense mutation [ 12 , 27 , 32 , 33 , 34 ]. All three of our compound heterozygous cases (cases 8, 10 and 13) carried an inferred null and a missense mutation, had a severe overlap syndrome with early childhood onset (<4 years), and NFCA events occurred in two of these cases.…”
Section: Discussionmentioning
confidence: 99%
“…Early age of onset is associated with severity in many genetic diseases. Although there are many isolated case-reports of SCN5A -channelopathy in children in the medical literature [ 8 , 9 , 10 , 11 , 12 , 13 , 14 ], few studies have analyzed SCN5A -channelopathy cohorts where onset of symptoms occurs in pediatric patients. A large prospective multi-center pediatric cohort of SCN5A mutation-positive neonates reported that 67.9% were asymptomatic at diagnosis, while age <1 year at diagnosis, compound heterozygous mutations, and mutations with both gain- and loss-of-function were identified as independent risk factors for cardiac events [ 15 ].…”
Section: Introductionmentioning
confidence: 99%
“…However, the notorious Nav1.5 may now emerge as a potential drug target. Recently, Nijak et al showed that nemertide 1 was able to restore the loss of function by reducing channel inactivation by binding to Na V 1.5 in a rare inherited cardiac arrhythmia . Nemertide 4 , which normally would be immediately disqualified as the most toxic peptide because it is the most active on Na V 1.5, might thus be the most interesting one.…”
Section: Resultsmentioning
confidence: 99%